Abstract
More than a century after its initial clinicopathologic description, amyotrophic lateral sclerosis (ALS) remains a largely fatal, progressive neurodegenerative disorder for which few efficacious pharmacotherapies with an impact directly on the natural course of the illness exist. The only currently approved therapy, the antiglutamatergic agent riluzole, has been shown to have only a marginal survival benefit in the absence of changes in functional assessments during the disease course. The efficacy of recombinant human insulin-like growth factor (rhIGF-1) remains controversial. In light of this, the primary focus of treatment for individuals with ALS remains symptomatic, through a multidisciplinary team approach including physicians, nurses, speech/language pathologists, physical therapists, occupational therapists, dietitians, social workers, and respiratory therapists.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
